DDO3602 |
Catalog No.GC81720
One-Click Copy Product Info
|
DDO3602 is a PARP1 HSPTAC ( HSP90 -mediated proteolysis-targeting chimera) degrader, with a DC50 of 490.3 nM against PARP1; its K d values for PARP1 and HSP90 are 66.5 nM and 1.64 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, DDO3602 (10-20 mg/kg; i.p.; every other day; 21 days) potently inhibits MCF-7 xenograft tumor growth in immunocompromised mice[1]. DDO3602 (20 mg/kg; i.v.; single dose) exhibits tumor-targeted pharmacokinetics in MCF-7 xenograft mice, with significantly higher accumulation in tumor tissue than normal tissues following a single 20 mg/kg intravenous dose[1].
In Vitro, DDO3602 (0-3 μM; 9 h) degrades PARP1 in human breast cancer MCF-7 cells in a dose-dependent manner, with a DC50 of 490.3 nM, and the degradation rate reaches 70.6% after incubation at 1 μM for 9 h[1]. DDO3602 (1 μM; 0-24 h) induces significant degradation of PARP1 in human breast cancer MCF-7 cells within 3 h, with nearly complete depletion achieved by 9 h[1]. DDO3602 (1 μM; 0-24 h) degrades the pre-existing PARP1 protein in MCF-7 human breast cancer cells, rather than inhibiting its synthesis[1]. DDO3602 (0-1 μM) exerts a stronger inhibitory effect on colony formation in human breast cancer MCF-7 cells than in normal mammary epithelial MCF-10A cells[1]. DDO3602 (0-10 μM; 72 h) inhibits the viability of MCF-7 human breast cancer cells with an IC50 of 0.189 μM; its potency is approximately 4-fold higher than that against MCF-10A normal mammary epithelial cells (IC50 = 0.744 μM) after 72 h of treatment[1]. DDO3602 (0.5-1 μM; 24 h) induces dose-dependent G2/M cell cycle arrest in human breast cancer MCF-7 cells[1]. DDO3602 (1 μM; 24 h) induces significant DNA double-strand break formation in MCF-7 human breast cancer cells (detected by γ-H2A.X accumulation)[1]. DDO3602 (0.1-1 μM; 48 h) significantly inhibits the migration of MCF-7 cells[1].
References:
[1]. Liu W, et al. HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment. Journal of medicinal chemistry. 2025 Oct 09;68(19):19933-19954.
| Cas No. | SDF | ||
| Formula | C51H58FN7O7 | M.Wt | 900.05 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.111 mL | 5.5552 mL | 11.1105 mL |
| 5 mM | 222.2 μL | 1.111 mL | 2.2221 mL |
| 10 mM | 111.1 μL | 555.5 μL | 1.111 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)